Triple-action approach tackles solid tumors: Shengshi Taikang’s innovative dual-target drug completes first subject dosing
Release date:
2022-07-06
Today, CGT-6321, a dual-target small-molecule inhibitor independently developed by Shengshi Taikang, completed dosing of the first subject in its Phase I clinical trial. With its highly selective mechanism, the drug can simultaneously target three pathways to effectively combat the proliferation of solid tumors, positioning itself as a potential "first-in-class" innovative therapy for solid tumor treatment in China.
CGT-6321 is a small-molecule inhibitor targeting both FGFR and VEGFR, designed for the treatment of patients with solid tumors such as liver cancer, gastric cancer, and colorectal cancer. Thanks to its highly selective kinase-inhibiting properties, the drug exerts a triple action: suppressing tumor cell growth, inhibiting angiogenesis, and modulating the tumor immune microenvironment. By blocking the downstream signaling of FGF/FGFR and VEGF/VEGFR pathways, CGT-6321 directly halts tumor cell proliferation. Additionally, it suppresses tumor-induced neo-angiogenesis, thereby improving the tumor microenvironment, and counteracts the immunosuppressive effects arising from the synergistic activation of FGF/VEGF pathways, ultimately inhibiting tumor cell growth, survival, proliferation, and migration.
The clinical trial for CGT-6321 is a multicenter, open-label, dose-escalation and expansion Phase Ia/Ib study designed to evaluate the drug's safety, tolerability, pharmacokinetic profile, and efficacy in patients with advanced solid tumors. It will also provide an initial assessment of the compound's anti-tumor activity and help identify specific solid tumor types that may respond favorably to treatment. The first subject has successfully received the study drug, marking the official entry of this clinical program into full-scale operational activities.